Shintaro Kanda

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer

Satoru Kitazono, Yutaka Fujiwara, Koji Tsuta et al. · Clinical Lung Cancer · 2015 · 136 citations

Non–small-cell Lung Cancer, Prognostic Biomarkers, Oncology +10

PD-L1 expression in neuroendocrine tumors of the lung

Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto et al. · Lung Cancer · 2017 · 124 citations · Full text

Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer

Tomonobu Koizumi, Kenji Tsushima, Tsuyoshi Tanabe et al. · Respiration · 2015 · 98 citations · Full text